In this work, we reported that a Chinese MN male associated with lung squamous cell carcinoma (LSCC) who had PD-L1 positive expression and high tumor mutation burden (TMB) level benefited from radiochemotherapy (RCT) following ICI (pembrolizumab). The gene discussed is CD274; the disease is neoplasm.